Patrick Adorjan
Zurich
Summary
A dynamic medical professional with a proven track record across diverse therapeutic areas, regions, and international organizations. Successfully spearheaded global and local medical strategies in pre- and post-launch phases, resulting in market penetration and broad patient access. Recognized for strong leadership and integrity, fostering cross-matrix relationships, both internally and externally, to drive evidence-based outcomes.
Overview
14
14
years of professional experience
Work History
Global Medical Lead Oncology
Bayer
Basel
05.2022 - Current
- Led the global launch for mHSPC indication of Darolutamide.
- Formulated and executed global medical strategies for prostate cancer, aligning with the brand vision and market needs.
- Aligned objectives and messaging across regional and country teams.
- Managed study-related planning activities, ensuring effective execution and supervision of conceptualization and protocols for phases 2 and 4 studies.
- Led the publication plan for studies, generating evidence in abstracts, posters, and manuscripts.
- Designed and implemented an internal training strategy to ensure the continuous education of global and country market access and medical affairs teams.
- Provided medical input into market research and health outcomes research conducted by commercial and market access teams.
- Ensured that strategy and execution partnered closely with product lead, biostatistics, and clinical development.
- Oversaw investigator-initiated studies, ensuring high-quality research and data integrity.
Medical Team Lead Alzheimer's Disease
Biogen
Baar
07.2020 - 03.2022
- Mentored, coached, and supervised the performance of direct reports, building a highly skilled, diverse, and inclusive team in a multifunctional matrix environment.
- Drove pre-launch activities for a new Alzheimer's disease drug, driving awareness and education among healthcare professionals.
- Prepared comprehensive medical affairs plans for product launch, ensuring readiness and strategic alignment.
- Supported regulatory submissions and developed educational materials for healthcare professionals, ensuring compliance and knowledge dissemination.
- Conducted market landscape assessments to inform strategic decisions and stakeholder communication.
Associate Medical Director Oncology EMEA
Astellas Pharma Europe
London
11.2017 - 12.2019
- Led the nmCRPC indication launch of Enzalutamide across EMEA, enhancing its market presence and adoption.
- Aligned medical strategies with global objectives, ensuring consistency across Europe, the Middle East, and Africa.
- Analyzed clinical trial data to inform regional strategies and tactics.
- Organized educational symposia at major medical congresses, enhancing knowledge and engagement.
- Developed risk minimization plans and established performance metrics to ensure safety and effectiveness.
Senior Medical Manager Oncology
Astellas Pharma Europe
London
11.2016 - 10.2017
- Led medical affairs teams across multiple European countries, fostering collaboration and strategic alignment.
- Developed sub-regional medical strategies, ensuring alignment with European objectives.
- Designed educational initiatives for healthcare professionals, enhancing their knowledge and skills.
- Ensured all medical activities aligned with country and regional regulations.
- Initiated and oversaw advisory board, roundtable discussions, and congress engagements.
- Provided medical input into market research and health outcomes research conducted by commercial and market-access teams.
Medical Manager Urology
Astellas
Zurich
09.2015 - 10.2016
- Developed local medical strategies for overactive bladder and benign prostate hyperplasia, driving market success.
- Built relationships with healthcare professionals and key opinion leaders, enhancing collaboration and advocacy.
- Conducted training sessions for sales teams, ensuring they were well-informed and effective.
- Developed and implemented medical education strategies.
- Developed and validated medical materials for external dissemination.
Medical Science Liaison
MSD Sharp & Dohme GmbH
Lucerne
10.2011 - 12.2014
- Cultivated strong presentation skills for educational sessions with healthcare professionals.
- Analyzed market trends and competitor activities to inform strategic decisions.
- Established and maintained relationships with key opinion leaders in rheumatology and pain management.
- Delivered engaging and informative presentations to various stakeholders, enhancing understanding and support.
- Educated and trained internal teams and healthcare professionals on product-related information.
Medical Doctor
Kantonsspital Winterthur
Winterthur
09.2010 - 08.2011
- Provided radiological services and supported clinical teams in diagnostic imaging, ensuring accurate diagnoses and patient care.
Education
MBA - Business Administration and Management, General
University of Strathclyde Business School
Glasgow, Scotland01-2022
Diploma of Advanced Studies in Pharmaceutical Medicine - Pharmaceutical Medicine
European Center of Pharmaceutical Medicine
Basel, Switzerland01-2015
M.D. - Medicine
University of Berne
Berne, Switzerland01-2010
Skills
- Strategic thinking
- Leadership
- Decisiveness
- Effective communication
- Adaptability
- Collaboration
- Resilience
- Innovative thinker
Publications selected
- ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR). Matthew Raymond Smith, Howard I. Scher, Frank Verholen, Patrick Adorjan, Manjari Dissanayake, Xin Gao. Journal of Clinical Oncology 2024 42:4_suppl, TPS243-TPS243.
- Darolutamide plus androgen-deprivation therapy (ADT) versus ADT in metastatic hormone-sensitive prostate cancer: Open-label single-arm study with an external control arm (ARASEC). Neal D. Shore, Mark A. Preston, Justin R Gregg, Simpa Samuel Salami, Ashley Ross, Amanda Bruno, Shankar Srinivasan, Niculae Constantinovici, Jorge A. Ortiz, Patrick Adorjan, Frank Verholen, Rana R. McKay. Journal of Clinical Oncology 2023 41:6_suppl, TPS297-TPS297.
- A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study. Matthew Raymond Smith, Howard I. Scher, Frank Verholen, Patrick Adorjan, Manjari Dissanayake, Andrew Leonard Laccetti. Journal of Clinical Oncology 2023 41:16_suppl, TPS5111-TPS5111.
- THIRD INTERIM ANALYSIS (IA3) OF THE DAROLUTAMIDE OBSERVATIONAL (DAROL) STUDY IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC). Gotto G, Suzuki H, Luz M, Briganti A, Yu EY, Pieczonka C, et al. J Urol. 2024;211(5S):e63.
- Health-related quality of life deterioration-free survival by prostate-specific antigen decline in darolutamide-treated patients with nonmetastatic castration-resistant prostate cancer from ARAMIS. Alicia K. Morgans, Christopher Sweeney, Christopher J.D. Wallis, Susan Halabi, Andrew J. Armstrong, Ateesha F. Mohamed, Patrick Adorjan, Frank Verholen, Shankar Srinivasan, Marc-Oliver Grimm. Presented at the European Society for Medical Oncology Conference, Madrid, Spain, October 20–24, 2023.
- Darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: Second interim analysis. Evan Y. Yu, Christopher Michael Pieczonka, Hiroyoshi Suzuki, James L. Bailen, Geoffrey T. Gotto, Joelle P. Hamilton, Hiroji Uemura, Declan G. Murphy, Thierry Lebret, Murilo de Almeida Luz, Jorge A. Ortiz, Patrick Adorjan, Javeed Khan, Alberto Briganti, Andrew J. Armstrong. Journal of Clinical Oncology 2023 41:16_suppl, e17095-e17095.
- Clinical outcomes after PCI for acute coronary syndrome in unprotected left main coronary artery disease: Insights from the Swiss Acute Left Main Coronary Vessel Percutaneous Management (SALVage) study. Puricel, Serban & Adorjan, Patrick & Oberhänsli, Markus & Stauffer, Jean-Christophe & Moschovitis, Aris & Vogel, Rolf & Goy, Jean-Jacques & Müller, Olivier & Eeckhout, Eric & Togni, Mario & Wenaweser, Peter & Meier, Bernhard & Windecker, Stephan & Cook, Stéphane. (2011). EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 7. 697-704. 10.4244/EIJV7I6A112.
- Iatrogenic left main coronary artery dissection: Incidence, classification, management, and long-term follow-up. Eshtehardi, Parham & Adorjan, Patrick & Togni, Mario & Tevaearai Stahel, Hendrik & Vogel, Rolf & Seiler, Christian & Meier, Bernhard & Windecker, Stephan & Carrel, Thierry & Wenaweser, Peter & Cook, Stéphane. (2010). American heart journal. 159. 1147-53. 10.1016/j.ahj.2010.03.012.
- Transient apical ballooning syndrome – Clinical characteristics, ballooning pattern, and long-term follow-up in a Swiss population. Eshtehardi, Parham & Koestner, Simon & Adorjan, Patrick & Windecker, Stephan & Meier, Bernhard & Hess, Otto & Wahl, Andreas & Cook, Stéphane. (2008). International journal of cardiology. 135. 370-5. 10.1016/j.ijcard.2008.03.088.
Languages
German
First Language
English
Proficient (C2)
C2
French
Advanced (C1)
C1
Hungarian
Advanced (C1)
C1
References
References available upon request.
Timeline
Global Medical Lead Oncology
Bayer
05.2022 - Current
Medical Team Lead Alzheimer's Disease
Biogen
07.2020 - 03.2022
Associate Medical Director Oncology EMEA
Astellas Pharma Europe
11.2017 - 12.2019
Senior Medical Manager Oncology
Astellas Pharma Europe
11.2016 - 10.2017
Medical Manager Urology
Astellas
09.2015 - 10.2016
Medical Science Liaison
MSD Sharp & Dohme GmbH
10.2011 - 12.2014
Medical Doctor
Kantonsspital Winterthur
09.2010 - 08.2011
MBA - Business Administration and Management, General
University of Strathclyde Business School
Diploma of Advanced Studies in Pharmaceutical Medicine - Pharmaceutical Medicine
European Center of Pharmaceutical Medicine
M.D. - Medicine
University of Berne